JanOne Inc. (JAN)

NASDAQ: JAN · IEX Real-Time Price · USD
1.630
+0.035 (2.19%)
At close: Mar 4, 2024, 4:00 PM
1.610
-0.020 (-1.23%)
After-hours: Mar 4, 2024, 7:41 PM EST
2.19%
Market Cap 7.91M
Revenue (ttm) 11.16M
Net Income (ttm) 11.16M
Shares Out 4.96M
EPS (ttm) 3.81
PE Ratio 0.43
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 503,748
Open 1.640
Previous Close 1.595
Day's Range 1.510 - 1.870
52-Week Range 0.220 - 1.870
Beta 2.18
Analysts n/a
Price Target n/a
Earnings Date Apr 15, 2024

About JAN

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral arte... [Read more]

Sector Industrials
Founded 1976
Employees 199
Stock Exchange NASDAQ
Ticker Symbol JAN
Full Company Profile

Financial Performance

Financial Statements

News

JanOne to Present at the Dawson James 8th Annual Investment Conference

Chief Medical Officer Dr. Amol Soin will explain innovative approaches to pain management and JanOne's development of non-addicting treatments for pain LAS VEGAS , Sept. 21, 2023 /PRNewswire/ -- JanOn...

5 months ago - PRNewsWire

JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference

Chief Medical Officer Dr. Amol Soin will discuss innovative approaches to pain management and JanOne's development of non-addicting treatments for pain LAS VEGAS , Aug. 31, 2023 /PRNewswire/ -- JanOne...

6 months ago - PRNewsWire

JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain

The Broad Patent Coverage is a Major Milestone for the Commercial Success of Jan123 LAS VEGAS , Aug. 29, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the visionary biotech company dedicated to discoveri...

6 months ago - PRNewsWire

JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual Meeting

Abstract explained Jan101's statistically significant reduction in pain and improvement in nerve conduction velocity in prior Phase II study. LAS VEGAS , Aug. 25, 2023 /PRNewswire/ -- JanOne (Nasdaq: ...

6 months ago - PRNewsWire

JanOne Technologies Announces Closing of Registered Direct Offering Priced At-The-Market under Nasdaq Rules

LAS VEGAS, Aug. 22, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN) (the "Company"), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of...

6 months ago - PRNewsWire

JanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq Rules

LAS VEGAS , Aug. 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN) (the "Company"), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes o...

7 months ago - PRNewsWire

JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting

JAN101 Showed Statistically Significant Reduction in Pain and Improvement in Nerve Conduction Velocity in Prior Phase II study. LAS VEGAS , Aug. 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopha...

7 months ago - PRNewsWire

JanOne files international patent application for methods of using low dose naltrexone to treat chronic pain

Patent filing marks another milestone in becoming a world leader in pain management LAS VEGAS , June 28, 2023 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a biopharmaceutical company that is developing ...

8 months ago - PRNewsWire

JanOne Completes Pre-IND Meeting with FDA on Jan123

JanOne (Nasdaq: JAN), the biopharmaceutical innovator specializing in non-addicting painkillers and new treatments for the causes of pain, has completed a successful pre-IND meeting with the FDA regar...

11 months ago - PRNewsWire

JanOne to Present Data On Its Two Non-Opioid Drug Candidates at The Appalachian Region Spine and Pain Meeting on Drug Development Programs to Treat Pain on April 15, 2023

LAS VEGAS , April 13, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), Dr. Amol Soin, Chief Medical Officer of JanOne, will be presenting at the Appalachian Region Spine and Pain Meeting in Sulfur Springs, ...

11 months ago - PRNewsWire

JanOne Technologies Announces Closing of Registered Direct Offering of Common Stock Priced At-The-Market

LAS VEGAS , March 24, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today a...

1 year ago - PRNewsWire

JanOne Welcomes John Bonfiglio -- Veteran Biotech Executive, Deal Maker and Strategist -- to Top Management Team

Bonfiglio is known for raising capital, building start-ups, and leading successful biotech companies as CEO and COO.      LAS VEGAS , March 23, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmace...

1 year ago - PRNewsWire

JanOne Technologies Announces Registered Direct Offering of Common Stock Priced At-The-Market

LAS VEGAS , March 23, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today a...

1 year ago - PRNewsWire

JanOne Sells Legacy Business ARCA Recycling to Concentrate on Growing BioPharm Businesses

Sale reduces liabilities by $17.6 million and entails at least $24 Million in future payments  LAS VEGAS , March 22, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing...

1 year ago - PRNewsWire

JanOne to Present Important Trial Results at Annual Meeting of American Society of Interventional Pain Physicians

JAN 123's in vitro study on low dose naltrexone vies for the Society's "Best Research Abstract of the Year"   LAS VEGAS , Feb. 22, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical compan...

1 year ago - PRNewsWire

JanOne Charts Ambitious Strategic Course for Non-Addictive Pain Management

In meetings hosted by Nasdaq MarketSite , the company reviewed its drug development programs that fight the opioid crisis through pharmaceuticals that reduce pain without causing addiction. LAS VEGAS ...

1 year ago - PRNewsWire

JanOne Inc. Completes Acquisition of Soin Therapeutics, LLC

The acquisition of Soin provides JanOne with its second, late stage clinical stage asset LAS VEGAS , Jan. 10, 2023 /PRNewswire/ -- JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the d...

1 year ago - PRNewsWire

JanOne Inc. Executes Term Sheet to Acquire Soin Therapeutics LLC

The acquisition of Soin will provide JanOne with its second clinical stage product LAS VEGAS , Sept. 16, 2022 /PRNewswire/ -- JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the develo...

1 year ago - PRNewsWire

ARCA Recycling, a Subsidiary of JanOne Inc., Unveils New Logo and Website

MINNEAPOLIS , July 5, 2022 /PRNewswire/ -- ARCA Recycling, Inc. (ARCA), a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), unveiled a new logo that aligns its visual identity with the innovative ...

1 year ago - PRNewsWire

JanOne Inc. Announces an Improved Formulation of JAN101

Recent Developments at the University of Iowa have Resulted in an Improved Formulation of JAN101 LAS VEGAS , June 28, 2022 /PRNewswire/ -- JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses ...

1 year ago - PRNewsWire

ARCA Recycling, Inc., a Subsidiary of JanOne Inc., Opens Three New Recycling Centers in Washington, California and New Jersey

MINNEAPOLIS , June 9, 2022 /PRNewswire/ -- ARCA Recycling, Inc., (ARCA), a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), will open three new recycling centers in June and July of this year to ...

1 year ago - PRNewsWire

Why JanOne Shares Are Skyrocketing Today

JanOne Inc (NASDAQ: JAN) shares are trading higher by 42.40% at $3.56 after the company announced that a patent was issued that covers a method of improving nerve function using JAN101. JAN101 (former...

1 year ago - Benzinga

JanOne Inc. Announces the Issuance of U.S. Patent Covering a Method of Improving Nerve Function Using JAN101

Issuance of U.S. Patent 11,247,902 B2 Further Bolsters JanOne Inc.'s Intellectual Patent Portfolio LAS VEGAS , June 7, 2022 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company that focuses on the dev...

1 year ago - PRNewsWire

Why JanOne Shares Are Trading Higher Today

JanOne Inc (NASDAQ: JAN) sold all of the assets, and none of the liabilities, of GeoTraq Inc., its wholly-owned subsidiary, to SPYR Inc (OTC: SPYR) for an aggregate of $13.5 million. The purchase pric...

1 year ago - Benzinga

JanOne Sells GeoTraq to SPYR Technologies in a $13.5 Million Transaction

Sale of GeoTraq allows JanOne to focus on core business strategy LAS VEGAS , May 31, 2022 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), announced today that it has sold substantially all of the assets, a...

1 year ago - PRNewsWire